Dysgeusia News and Research

RSS
FDA approves first therapy for symptomatic tenosynovial giant cell tumor

FDA approves first therapy for symptomatic tenosynovial giant cell tumor

FDA approves new treatment for AML patients

FDA approves new treatment for AML patients

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

FDA grants approval for first drug to treat inherited breast cancer

FDA grants approval for first drug to treat inherited breast cancer

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

FDA grants approval to first biosimilar for treatment of patients with breast, stomach cancers

FDA grants approval to first biosimilar for treatment of patients with breast, stomach cancers

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

FDA approves new maintenance therapy for recurrent cancers

FDA approves new maintenance therapy for recurrent cancers

FDA awards accelerated approval to new ovarian cancer drug

FDA awards accelerated approval to new ovarian cancer drug

Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients

Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients